Recruiting

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885 · InventisBio Co., Ltd

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis

About this study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis

Eligibility criteria

Inclusion Criteria: * Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent * Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3. * Within normal ranges of laboratory assessments Exclusion Criteria: * Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Study design

Enrollment target: 75 participants

Allocation: randomized

Masking: quadruple

Age groups: adult, older_adult

Timeline

Starts: 2026-06-03

Estimated completion: 2027-12

Last updated: 2026-07-09

Interventions

Drug: D-2570 TabletDrug: Placebo Tablets

Primary outcomes

• Improvement in PASI-90 (Assessment completed after 12 weeks of treatment/placebo)

Sponsor

InventisBio Co., Ltd · industry

Contacts & investigators

ContactKathryn Stazzone · contact · kathryn.stazzone@inventisbio.com · 3025195966